Nykode Therapeutics AS (VACBF) Q2 2026 Earnings Call Transcript

SA Transcripts 162.01K Followers Follow Nykode Therapeutics AS ( VACBF ) Q2 2026 Earnings Call August 26, 2026 3:00 AM EDT Company Participants Michael Engsig - Chief Executive Officer Agnete Fredriksen - Co-Founder & Chief Scientific Officer Harald Gurvin - Chief Financial Officer Presentation Operator Greetings, and welcome to the Nykode Therapeutics Q2 2026 Financial Results Presentation. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to CEO, Michael Engsig. Please go ahead, sir. Michael Engsig Chief Executive Officer Thank you very much, Kevin, and also from my side, a very warm welcome, and good morning to all participants on this quarterly results presentation. We assume you are familiar with our forward-looking statements. And on that note, we'll move forward. As usual, I am very pleased to have with me here today, Agnete Fredriksen, our Co-Founder and Chief Scientific Officer and Head of Business Development; as well as Harald Gurvin, our CFO. For those not familiar with Nykode, just a few words on the company. Nykode is a clinical-stage immunotherapy company with a focus on oncology and autoimmune diseases. Our lead asset is abi-suva, a therapeutic cancer vaccine targeted against HPV16-driven cancer types. We have encouraging results across 3 different indications, 3 trials with close to 100 patients in total, which gave us the confidence to move into the first randomized Phase II trial in first-line head and neck, which is ongoing and called Abili-T, on track to deliver the first interim results in 2027. Our second clinical asset is VB10.NEO, which is an individualized neoantigen therapy. We saw some very important validating results from the field last week, and we'll, of course, be discussing that more in depth at this call here. We have clinical data from VB10.NEO from more than 10 tumor types. And based on the manufacturing process, which, of course, around pDNA as the